The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
A clinical study of Kang Ai injection combined with pemetrexed and cisplatin in the treatment of lung adenocarcinoma
Pages: 512-514
Year: Issue:  5
Journal: Oncology Progress

Abstract: Objective To investigate the clinical efficacy and adverse reactions of Kang Ai injection combined with pemetrexed and cisplatin in the treatment of lung adenocarcinoma. Method 100 patients with lung adenocarcinoma were enrolled and divided into treatment group (Kang Ai injection+pemetrexed+cisplatin) and control group (peme-trexed+cisplatin) by a random table, with 50 cases in each group. The clinical efficacy, adverse reactions and survival rates were compared between two groups. Result The objective response rate of both groups was 50%, and there was no significant difference. The incidences of grade 1 to 3 leucopenia and thrombocytopenia, nausea and vomiting were 34%, 12%and 76%in treatment group,and 62%, 36%and 86%in control group, all the differences were statistically signifi-cant (P<0.05). The incidences of decreased hemoglobin and elevated transaminase level were similar in treatment group and control group, and the differences were not statistically significant (P>0.05). The 1-year survival rate in treatment group and control group was 60.4%and 56.6%, respectively, and the 2-year survival rate was 27.4%and 29.0%, respec-tively, the differences were not statistically significant (P>0.05). Conclusion The combination therapy of Kang Ai injec-tion, pemetrexed and cisplatin can improve the quality of life of patients with lung adenocarcinoma, and reduce adverse reactions. It is worthy of clinical application.
Related Articles
No related articles found